Anxiety and Activity Tests –Fear Conditioning (FC)
Assess anxiety-related phenotypes
Key Research Model Applications of Fear Conditioning
Fear Conditioning (FC) is a widely used test to assess anxiety-related phenotypes in mice, as well as learning and memory. In the FC test, mice learn to associate an aversive stimulus with a neutral context or stimulus, resulting in a freezing response to the previously neutral stimulus.
Mouse Behavioral Testing Made Simple.
Explore our extensive portfolio of validated and tailored behavioral and cognitive rodent tests designed to advance your research.
Fear Conditioning Sample Data
A fear conditioning box is used to measure contextual fear learning and memory.
The Fear conditioning test consists of 2 days. The first day (training), mice receive 1 mild electrical foot shock that is connected with a background condition (noise, scent). Day after receiving a mild electrical shock, mice are placed in the same box for 180 seconds and freezing duration is measured. Freezing duration is used as a measure of intact learning and memory performance.
A fear conditioning box is used to measure contextual fear learning and memory.
Stxbp1 +/- mice mimic cognitive impairments observed in epileptic patients that can be detected during a fear conditioning assay.
A fear conditioning box is used to measure contextual fear learning and memory.
WT mice spend on average more time freezing than Fmr1 KO mice, confirming that Fmr1 KO mice have a deficiency in recalling contextual fear memory (P=0.01).
The People Behind Your Research
Thomas Vogels, PhD, In Vivo Neurology Study Director
Leads an expert team of scientists with vast experience in our Neurology models to help you choose the right model and guide your optimal study design. We provide the solution to accelerating your drug development.
Stay Curious: More Articles to Explore
![InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025](https://www.innoserlaboratories.com/wp-content/uploads/2025/03/ADPD-2025-InnoSer-Neurodegenerative-Disease-Models-1080x628.png)
InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025
We are excited to announce that InnoSer, as an innovative European preclinical neurodegenerative disease CRO, will be actively participating in the upcoming ADPD 2025 conference, taking place in Vienna, Austria from 1st to 5th April 2025. The ADPD 2025 Conference is...
InnoSer Strengthens Neurology Platform with Acquisition of remynd’s CRO Business
InnoSer’s acquisition of remynd’s CRO business further strengthens its neurology platform by integrating specialized neurodegenerative mouse models, expanding its service portfolio for Alzheimer’s and Parkinson’s diseases. Diepenbeek, Belgium – March 4th – InnoSer, a...
Gene Therapy Delivery Strategies: Helping You Address Challenges for CNS Diseases
With several recent gene therapy approvals in the CNS space and more on the horizon, the field of both genetic and neurodegenerative diseases is experiencing a transformative era. However, translating these therapies from preclinical research to clinical application...
How to Advance your Preclinical Research Using Mouse Data to Establish PK/PD Relationships
The major objective of early drug development is to select the most promising compounds and establish safe and effective doses and dosing regimens. To do so, an analysis of both the pharmacokinetic (PK) and pharmacodynamic (PD) properties of your novel compound needs...
info@innoserlaboratories.com